Truist Financial Issues Pessimistic Forecast for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD) had its price objective reduced by equities researchers at Truist Financial from $16.00 to $15.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s price target would suggest a potential upside of 19.43% from the stock’s current price.

Several other equities analysts have also recently weighed in on the stock. StockNews.com cut shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research report on Thursday, December 19th. Mizuho upped their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Jefferies Financial Group raised their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Macquarie started coverage on Pediatrix Medical Group in a report on Monday, December 16th. They issued an “outperform” rating and a $18.00 target price on the stock. Finally, UBS Group increased their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $16.25.

Pediatrix Medical Group Trading Down 1.9 %

Shares of NYSE MD opened at $12.56 on Monday. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group has a 12 month low of $6.62 and a 12 month high of $16.41. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -4.10, a P/E/G ratio of 2.00 and a beta of 1.58. The business has a fifty day simple moving average of $14.34 and a 200-day simple moving average of $11.52.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.29 earnings per share. Sell-side analysts predict that Pediatrix Medical Group will post 1.26 EPS for the current year.

Insider Buying and Selling

In other Pediatrix Medical Group news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP boosted its holdings in shares of Pediatrix Medical Group by 1.5% during the 3rd quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock worth $95,907,000 after buying an additional 125,000 shares during the period. State Street Corp boosted its holdings in Pediatrix Medical Group by 1.4% during the third quarter. State Street Corp now owns 3,540,791 shares of the company’s stock valued at $41,038,000 after acquiring an additional 50,597 shares during the period. Geode Capital Management LLC grew its position in shares of Pediatrix Medical Group by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock valued at $22,452,000 after purchasing an additional 45,155 shares during the last quarter. Dana Investment Advisors Inc. increased its stake in shares of Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after purchasing an additional 455,785 shares during the period. Finally, Weiss Asset Management LP lifted its position in shares of Pediatrix Medical Group by 50.5% during the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after purchasing an additional 306,143 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.